<DOC>
	<DOCNO>NCT02054559</DOCNO>
	<brief_summary>To compare efficacy safety chemotherapy alone combine modality therapy treatment localize CD20 ( + ) diffuse large B-cell lymphoma</brief_summary>
	<brief_title>R-CHOP Alone vs. R-CHOP Plus Radiotherapy Localized CD20+ DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Written inform consent Histologically confirm CD20positive Diffuse Large Bcell Lymphoma ( DLBCL ) , NOS Immunostains CD20 , CD5 , CD3 , CD10 , MUM1 , BCL6 , BCL2 Ki67 situ hybridization EpsteinBarr virus recommend diagnosis DLBCL , NOS . No prior treatment DLBCL Stage I contiguous II disease ( Involvement two adjacent lymph node region organ involvement regional lymph node ) Performance status : ECOG 02 . Age ≥ 18 year Cardiac ejection fraction ≥ 45 % measure MUGA 2D ECHO without clinically significant abnormality Adequate renal function : serum creatinine level &lt; 2 mg/dL Adequate liver function Adequate hematological function : hemoglobin ≥ 9.0 g/dL absolute neutrophil count ( ANC ) ≥ 1,500/μL platelet count ≥ 75,000/μL , unless abnormality due bone marrow involvement lymphoma Life expectancy &gt; = 6 month A negative serum urine pregnancy test prior treatment must available pre menopausal woman woman &lt; 1 year onset menopause . Female patient child bear potential must use effective method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide abstinence ) treatment period 1 month thereafter ; Males must use effective method birth control treatment period 3 month thereafter . Other subtypes NHL CD20 ( + ) DLBCL , NOS Transformed DLBCL follicular lymphoma indolent lymphoma Bulky disease ( long diameter &gt; =10 cm ) Previous treatment DLBCL immunotherapy chemotherapy except shortterm corticosteroid ( duration ≤ 8 day ) inclusion CNS involvement lymphoma evidence spinal cord compression . Primary Central Nervous System ( CNS ) DLBCL Primary testicular lymphoma Primary breast lymphoma Patients known history HIV seropositivity HCV ( + ) . ( Patients HBV ( + ) eligible . However , primary prophylaxis use antiviral agent ( i.e . lamivudine , etc ) recommend HBV carrier prevent HBV reactivation whole treatment period . ) Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin , early gastric cancer carcinoma situ cervix breast untreated prostatic cancer without plan treatment ) unless patient free disease ≥ 3 year Pregnant lactating woman Men surgically sterile woman childbearing potential employ adequate contraception Other serious illness medical condition Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry History significant neurological psychiatric disorder include dementia seizure Active uncontrolled infection ( viral , bacterial fungal infection ) Other serious medical illness Known hypersensitivity study drug ingredient Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>localize</keyword>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>R-CHOP chemotherapy</keyword>
	<keyword>radiotherapy</keyword>
</DOC>